An interventional study of Caffeine 300 MG and Placebo in Healthy Adult Male, sponsored by Comenius University. Completed at 1 site in Slovakia. Open to male participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Comenius University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing caffeine in Motor Activity — 2 open to participants now, 2 under way, none of them phase 3. Caffeine · Motor Activity.
Among the 13 studies testing caffeine in Motor Activity, this one is the 10th largest by enrollment, is one of 2 that started in 2024, is one of 11 with no phase, and was the 13th registered.
9,827 studies on the registry are indexed under Motor Activity; 1,911 are open to participants now.
Browse Motor Activity studies →2 of the 13 studies testing caffeine in Motor Activity are open now, in 2 countries. Recruiting first, the newest first:
Jagiellonian University · Sites in Poland
Ages 18–30 · Healthy volunteers
Universidad Rey Juan Carlos · Sites in Spain
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
Caffeine: first FDA approval 1948 (CAFERGOT), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 1,207 Motor Activity studies recruiting now, 524 (43%) set no upper age limit and 538 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.
This study: 18 Years to 35 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2024.
This study's enrollment of 16 is below the median of 60 across 8,412 interventional studies indexed under Motor Activity.
Median enrollment 23 across the 13 interventional studies. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 10 most frequent:
Comenius University is the lead sponsor of 42 studies on the registry; 11 are open to participants now.
Comenius University has 6 studies filed under Motor Activity — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing caffeine in Motor Activity, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized, double-blind, placebo-controlled crossover clinical trial aims to investigate the acute effects of caffeine supplementation on motor and perceptual-cognitive components of agility performance in male amateur soccer players.
The main questions are: i) Does acute caffeine supplementation improve motor performance, including countermovement jump height, drop-jump reactive strength, and planned agility? ii) Does acute caffeine supplementation improve perceptual-cognitive performance during reactive agility tasks involving light and human stimuli?
Participants will complete two experimental conditions in randomized order, receiving either 300 mg of caffeine (\~3.7 miligrams/kilograms of body mass) or placebo pills. Following ingestion, participants will perform countermovement and drop jumps and three Y-shaped agility tests assessing planned agility, reactive agility to a light stimulus, and reactive agility to a human stimulus.
Caffeine supplementation was investigated for its potential to differentially affect motor and perceptual-cognitive aspects of performance in athletes. Participants were recruited from amateur soccer clubs competing in the third to fifth tiers of the Slovak league system and fifth to sixth tiers of the Austrian league system. A pre-selection questionnaire was used to assess relevant demographic, sporting, health, injury, and habitual caffeine consumption characteristics. Players with habitual caffeine intake above 400 miligrams/day were excluded. A familiarization session was conducted approximately one week before the experimental measurements to practice the procedures and reduce learning effects.
The intervention consisted of a single 300 milligrams caffeine dose, corresponding to approximately 3.7 miligrams/kilograms of body mass. The placebo consisted of potato starch. Caffeine and placebo capsules were visually identical. Condition order was determined by simple randomization using an independent online randomization generator, and the investigator responsible for randomization was not involved in testing. Participants and testers remained unaware of the assigned condition.
Participants were instructed to maintain their usual training regimen, abstain from caffeine-containing products for at least 24 hours before testing, and avoid intense physical activity on the preceding day. The two experimental sessions were conducted seven days apart, during the same period of the soccer season and at the same time of day to reduce potential effects of recovery and circadian variation. Diet, fluid intake, and sleep were not standardized.
After capsule ingestion, participants completed a standardized dynamic warm-up involving aerobic activation, lunges, dynamic stretching, and countermovement jumps. Testing subsequently assessed explosive lower-limb performance and agility under controlled laboratory and field conditions. The agility assessment used a Y-shaped setup and distinguished between a predetermined change-of-direction task and reactive tasks requiring a response to either a visual light stimulus or a live human stimulus.
The human-stimulus condition was designed to introduce a greater perceptual and decision-making component than the planned condition. Participants were required to perceive the tester's movement and rapidly select the appropriate alternative direction. Reactive trials were repeated when predefined technical errors, incorrect responses, slips, or other invalid performances occurred.
The experimental procedures were completed within a short testing window following supplementation to correspond with the expected onset of caffeine's acute physiological effects. The fixed testing sequence was maintained across both experimental conditions to ensure consistency between visits.
The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Faculty of Physical Education and Sport, Comenius University in Bratislava (Approval Number 15/2024). All participants provided written informed consent before participation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Supplementation was administered as caffeine capsules (Scitec Nutrition Caffeine, 100 milligrams per capsule). Participants received 300 mg of caffeine, which represented approximately 3.74 milligrams/kilograms of mean body mass. This dosage corresponded to an individual dose ranging from 3.16 to 4.44 milligrams/kilograms of mean of body mass. The capsules were visually identical, and neither the testers nor the participants were aware of the assigned condition. Caffeine was ingested 30 minutes before the testing session.
Dietary Supplement: Caffeine 300 MG
Supplementation was administered as a placebo capsules filled with potato starch. The capsules were visually identical, and neither the testers nor the participants were aware of the assigned condition. Placebo pills were ingested 30 minutes before the testing session.
Dietary Supplement: Placebo
Supplementation was administered as caffeine capsules (Scitec Nutrition Caffeine, 100 milligrams per capsule). Subjects received 300 milligrams of caffeine, which represented an individual dose ranging from 3.16 to 4.44 milligrams/kilograms of body mass.
Also known as: caffeine pills
Supplementation was administered as placebo capsules filled with potato starch. The capsules were visually identical, and neither the testers nor the participants were aware of the assigned condition.
Planned Agility
The running course was divided into two sections. The first section consisted of a 5 meter linear sprint from a two-point starting position. At the end of the linear section, two cones positioned 1-meter apart marked the change-of-direction area. The participant was instructed by the tester to change the direction of sprinting by cutting at a 45° angle to either the left or right side. The primary outcome measure was the fastest trial completion time, recorded in seconds using a photocell timing system. Timing commenced when the participant crossed the starting gate and ended when the participant crossed the designated gate at the end of course.
Time frame: 40 minutes after caffeine/placebo ingestion
Reactive Agility
The running course was divided into two sections. The first section consisted of a 5 meter linear sprint from a two-point starting position. At the end of the linear section, two cones positioned 1-meter apart marked the change-of-direction area. The participant was instructed by the tester to change the direction of sprinting according to the a) light sensor, b) human movement, by cutting at a 45° angle to either the left or right side. 1. Light sensor showed green arrow of dedicated change-of-direction. This stimulus occured 500 milliseconds after crossing the starting gate. 2. Human tester executed movement to the side when participants were 2.5 meters apart from starting gate. Participants were reacting by the execution of change-of-direction to the opposite side as human tester. The outcome was the fastest completion time, recorded in seconds using a photocell timing system.
Time frame: 45 minutes after caffeine/placebo ingestion
Countermovement jump
Assessment of vertical power production by the lower limbs, evaluated as maximum countermovement jump height in centimeters.
Time frame: 30 minutes after caffeine/placebo ingestion
Drop jump 30
Assessment of reactive strength of the lower limbs, evaluated as the maximum reactive strength index (RSI) calculated from flight time and contact time during a drop jump from a 30 centimeter box.
Time frame: 35 minutes after caffeine/placebo ingestion
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2024 to primary completion in Oct 2024, 0 months.
Of 5,176 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's 0 months is below that.
Counting every sponsor, half of 5,236 studies reached it within 17 months; a quarter within 7 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Caffeine
Comenius University